Search Result

Results for "

Human corticotropin-releasing factor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CRFR (13) Bacterial (3) Drug Derivative (1) ERK (3) mRNA (1) NF-κB (3) Parasite (3) Reference Standards (2)
By Research Areas:	Cardiovascular Disease (2) Endocrinology (4) Metabolic Disease (4) Neurological Disease (9)
Oligonucleotides:	Transcription Factors (1) mRNA (1)

Inhibitors & Agonists

Peptides

Recombinant Proteins

Oligonucleotides

Targets Recommended: CRFR

Art. -Nr.	Produktname	Target	Forschungsgebiete	Chemical Structure

HY-P0086

Corticotropin-releasing factor (human) 3 Publications Verification Human CRF; Human corticotropin-releasing factor	CRFR	Neurological Disease
Corticotropin-releasing factor human (Human CRF) stimulates the synthesis and secretion of adrenocorticotropin in the anterior pituitary.

HY-P1752

Urocortin II, human	CRFR Bacterial Parasite NF-κB ERK	Metabolic Disease
Urocortin II, human is a selective endogenous peptide agonist of *type-2 corticotropin-releasing* factor (CRF2) receptor*. Urocortin II, human* has an effect of promoting satiet and neuroprotective effect. Urocortin II, human also has bactericidal, antiparasitic and pro-inflammation activity. Urocortin II, human can activate NF-κB pathway and ERK1/2 MAP kinase. Urocortin II, human can reduce pulmonary arterial hypertension and shows cardiac protection effect. Urocortin II, human can be used for the researches of infection, inflammation, metabolic, neurological and cardiovascular disease .

HY-135542

NBI-27914 2 Publications Verification	CRFR	Others
NBI-27914 is a highly selective, high-affinity non-peptide competitive antagonist of human corticotropin-releasing factor receptor 1 (CRFR1). NBI-27914 primarily binds to the His199 and Met276 sites in the transmembrane domain of the receptor .

HY-12127

Pexacerfont BMS-562086	CRFR	Neurological Disease Endocrinology
Pexacerfont is a selective corticotropin-releasing factor (CRF₁) receptor antagonist with IC₅₀ of 6.1±0.6 nM for human CRF₁ receptor.

HY-P3019

Urocortin III (human)	CRFR	Cardiovascular Disease Neurological Disease Endocrinology
Urocortin III (human) is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) potently binds to type 2 CRF receptors, specifically mCRF_2β (K_i = 13.5 nM) and rCRF_2α (K_i = 21.7 nM), while demonstrating negligible affinity for hCRF1 (K_i >100 nM). Urocortin III (human) mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion ^[1][2].

HY-P1752B

Urocortin II, human acetate	CRFR Bacterial Parasite NF-κB ERK	Metabolic Disease
Urocortin II, human acetate is a selective endogenous peptide agonist of *type-2 corticotropin-releasing* factor (CRF2) receptor*. Urocortin II, human* acetate has an effect of promoting satiet and neuroprotective effect. Urocortin II, human acetate also has bactericidal, antiparasitic and pro-inflammation activity. Urocortin II, human acetate can activate NF-κB pathway and ERK1/2 MAP kinase. Urocortin II, human acetate can reduce pulmonary arterial hypertension and shows cardiac protection effect. Urocortin II, human acetate can be used for the researches of infection, inflammation, metabolic, neurological and cardiovascular disease .

HY-P3684A

*[DPro5] Corticotropin Releasing* Factor, human, rat TFA**	CRFR	Neurological Disease
[DPro5] Corticotropin Releasing Factor, human, rat TFA is a selective corticotropin releasing factor/hormone R2 (CRH-R2)agonist. [DPro5] Corticotropin Releasing Factor, human, rat TFA fails to cause the typical anxiogenic effect, but modulates learning and memory processes in rat .

HY-P3019A

Urocortin III (human) TFA	CRFR	Cardiovascular Disease Neurological Disease Metabolic Disease
Urocortin III (human) TFA is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) TFA preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) TFA potently binds to type 2 CRF receptors, specifically mCRF_2β (K_i = 13.5 nM) and rCRF_2α (K_i = 21.7 nM), while demonstrating negligible affinity for hCRF1 (K_i >100 nM). Urocortin III (human) TFA mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion .

HY-P3684

*[DPro5] Corticotropin Releasing* Factor, human, rat**	CRFR	Endocrinology
[DPro5] Corticotropin Releasing Factor, human, rat is a selective R2 agonist of corticotropin releasing factor/hormone. Corticotropin releasing factor (CRF) is a hypothalamic hormone, stimulates the release of adrenocorticotropic hormone (ACTH) and of β-endorphin. [DPro5] Corticotropin Releasing Factor, human, rat fails to cause the typical anxiogenic effect, but modulates learning and memory processes in rat .

HY-12127R

Pexacerfont (Standard) BMS-562086 (Standard)	CRFR Reference Standards	Neurological Disease Endocrinology
Pexacerfont (Standard) is the analytical standard of Pexacerfont. This product is intended for research and analytical applications. Pexacerfont is a selective corticotropin-releasing factor (CRF1) receptor antagonist with IC50 of 6.1±0.6 nM for human CRF1 receptor.

HY-14132

BMS-665053	CRFR	Neurological Disease
BMS-665053 is a corticotropin-releasing factor-1 (CRF1) receptor antagonist (IC₅₀ = 1.0 nM). BMS-665053)11 is a potent inhibitor of CRF-stimulated cyclic adenosine monophosphate (cAMP) production in human Y-79 retinoblastoma cells (IC₅₀ = 4.9 nM) .

HY-174545

Human POU3F2 mRNA	mRNA	Neurological Disease
Human POU3F2 mRNA encodes the human POU class 3 homeobox 2 (POU3F2) protein, a member of the POU-III class of neural transcription factors. POU3F2 is involved in neuronal differentiation and enhances the activation of corticotropin-releasing hormone regulated genes.

HY-135542R

NBI-27914 (Standard)	CRFR Reference Standards	Others
NBI-27914 (Standard) is the analytical standard of NBI-27914 (HY-135542). This product is intended for research and analytical applications. NBI-27914 is a highly selective, high-affinity non-peptide competitive antagonist of human corticotropin-releasing factor receptor 1 (CRFR1). NBI-27914 primarily binds to the His199 and Met276 sites in the transmembrane domain of the receptor.

HY-P1752A

Urocortin II, human TFA	CRFR Bacterial Parasite NF-κB ERK	Metabolic Disease
Urocortin II, human TFA is a selective endogenous peptide agonist of *type-2 corticotropin-releasing* factor (CRF2) receptor*. Urocortin II, human* TFA has an effect of promoting satiet and neuroprotective effect. Urocortin II, human TFA also has bactericidal, antiparasitic and pro-inflammation activity. Urocortin II, human TFA can activate NF-κB pathway and ERK1/2 MAP kinase. Urocortin II, human TFA can reduce pulmonary arterial hypertension and shows cardiac protection effect. Urocortin II, human TFA can be used for the researches of infection, inflammation, metabolic, neurological and cardiovascular disease .

HY-P11461

Biotin-CRF, human, rat Biotin-corticotropin releasing factor	Drug Derivative	Neurological Disease
Biotin-CRF, human, rat is a biotin-conjugated CRF (human, rat). CRF (human, rat) is a corticotropin-releasing hormone, paraventricular hypothalamic nucleus marker .

Art. -Nr.	Produktname	Target	Research Area

HY-P0086

Corticotropin-releasing factor (human) 3 Publications Verification Human CRF; Human corticotropin-releasing factor	CRFR	Neurological Disease
Corticotropin-releasing factor human (Human CRF) stimulates the synthesis and secretion of adrenocorticotropin in the anterior pituitary.

HY-P1752

Urocortin II, human	CRFR Bacterial Parasite NF-κB ERK	Metabolic Disease
Urocortin II, human is a selective endogenous peptide agonist of *type-2 corticotropin-releasing* factor (CRF2) receptor*. Urocortin II, human* has an effect of promoting satiet and neuroprotective effect. Urocortin II, human also has bactericidal, antiparasitic and pro-inflammation activity. Urocortin II, human can activate NF-κB pathway and ERK1/2 MAP kinase. Urocortin II, human can reduce pulmonary arterial hypertension and shows cardiac protection effect. Urocortin II, human can be used for the researches of infection, inflammation, metabolic, neurological and cardiovascular disease .

HY-P3019

Urocortin III (human)	CRFR	Cardiovascular Disease Neurological Disease Endocrinology
Urocortin III (human) is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) potently binds to type 2 CRF receptors, specifically mCRF_2β (K_i = 13.5 nM) and rCRF_2α (K_i = 21.7 nM), while demonstrating negligible affinity for hCRF1 (K_i >100 nM). Urocortin III (human) mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion ^[1][2].

HY-P1752B

Urocortin II, human acetate	CRFR Bacterial Parasite NF-κB ERK	Metabolic Disease
Urocortin II, human acetate is a selective endogenous peptide agonist of *type-2 corticotropin-releasing* factor (CRF2) receptor*. Urocortin II, human* acetate has an effect of promoting satiet and neuroprotective effect. Urocortin II, human acetate also has bactericidal, antiparasitic and pro-inflammation activity. Urocortin II, human acetate can activate NF-κB pathway and ERK1/2 MAP kinase. Urocortin II, human acetate can reduce pulmonary arterial hypertension and shows cardiac protection effect. Urocortin II, human acetate can be used for the researches of infection, inflammation, metabolic, neurological and cardiovascular disease .

HY-P3684A

*[DPro5] Corticotropin Releasing* Factor, human, rat TFA**	CRFR	Neurological Disease
[DPro5] Corticotropin Releasing Factor, human, rat TFA is a selective corticotropin releasing factor/hormone R2 (CRH-R2)agonist. [DPro5] Corticotropin Releasing Factor, human, rat TFA fails to cause the typical anxiogenic effect, but modulates learning and memory processes in rat .

HY-P3019A

Urocortin III (human) TFA	CRFR	Cardiovascular Disease Neurological Disease Metabolic Disease
Urocortin III (human) TFA is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) TFA preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) TFA potently binds to type 2 CRF receptors, specifically mCRF_2β (K_i = 13.5 nM) and rCRF_2α (K_i = 21.7 nM), while demonstrating negligible affinity for hCRF1 (K_i >100 nM). Urocortin III (human) TFA mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion .

HY-P3684

*[DPro5] Corticotropin Releasing* Factor, human, rat**	CRFR	Endocrinology
[DPro5] Corticotropin Releasing Factor, human, rat is a selective R2 agonist of corticotropin releasing factor/hormone. Corticotropin releasing factor (CRF) is a hypothalamic hormone, stimulates the release of adrenocorticotropic hormone (ACTH) and of β-endorphin. [DPro5] Corticotropin Releasing Factor, human, rat fails to cause the typical anxiogenic effect, but modulates learning and memory processes in rat .

HY-P1752A

Urocortin II, human TFA	CRFR Bacterial Parasite NF-κB ERK	Metabolic Disease
Urocortin II, human TFA is a selective endogenous peptide agonist of *type-2 corticotropin-releasing* factor (CRF2) receptor*. Urocortin II, human* TFA has an effect of promoting satiet and neuroprotective effect. Urocortin II, human TFA also has bactericidal, antiparasitic and pro-inflammation activity. Urocortin II, human TFA can activate NF-κB pathway and ERK1/2 MAP kinase. Urocortin II, human TFA can reduce pulmonary arterial hypertension and shows cardiac protection effect. Urocortin II, human TFA can be used for the researches of infection, inflammation, metabolic, neurological and cardiovascular disease .

HY-P11461

Biotin-CRF, human, rat Biotin-corticotropin releasing factor	Drug Derivative	Neurological Disease
Biotin-CRF, human, rat is a biotin-conjugated CRF (human, rat). CRF (human, rat) is a corticotropin-releasing hormone, paraventricular hypothalamic nucleus marker .

Art. -Nr.	Compare	Produktname	Species	Source	Image

HY-P70013

	CRHBP Protein, Human (HEK293, His) rHucorticotropin-releasing factor-binding protein/CRHBP, His ; corticotropin-releasing factor-Binding Protein; CRF-BP; CRF-Binding Protein; corticotropin-releasing Hormone-Binding Protein; CRH-BP; CRHBP; CRFBP	Human	HEK293
	CRHBP Protein critically regulates by binding to and inactivating corticotropin-releasing factor (CRF), suggesting a role in preventing excessive pituitary-adrenal stimulation, especially during pregnancy. This interaction contributes to balancing neuroendocrine signaling pathways, ensuring appropriate physiological responses and safeguarding against pituitary-adrenal axis overstimulation, particularly in the context of pregnancy. CRHBP Protein, Human (HEK293, His) is the recombinant human-derived CRHBP protein, expressed by HEK293 , with C-6*His labeled tag.

Compare Products


Products	Auf Lager - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / Auf Lager - + In den Warenkorb hinzufügen Angebot einholen

Art. -Nr.	Produktname		Classification

HY-174545

Human POU3F2 mRNA		mRNA Transcription Factors
Human POU3F2 mRNA encodes the human POU class 3 homeobox 2 (POU3F2) protein, a member of the POU-III class of neural transcription factors. POU3F2 is involved in neuronal differentiation and enhances the activation of corticotropin-releasing hormone regulated genes.

Online-Anfrage

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Anrede			Country or Region *
Name des Antragstellers *			Name der Organisation *
Department *
E-Mail-Addresse *			Produktname *
Art. -Nr.			Requested quantity *
Telefonnummer *
Bemerkungen

Online-Anfrage

Inquiry Information

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.